戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tment modalities are variables implicated in thrombophilia.
2  with recurrent pregnancy loss and inherited thrombophilia.
3 bnormalities or family history suggestive of thrombophilia.
4 , obesity, vaccination status, and inherited thrombophilia.
5 able to that seen with established monogenic thrombophilia.
6 ore pregnancy losses and confirmed inherited thrombophilia.
7 s explored signs of systemic inflammation or thrombophilia.
8 ntation candidates, and those with inherited thrombophilia.
9 disorders, immunodeficiency, malignancy, and thrombophilia.
10 al and genetic tests to diagnose this severe thrombophilia.
11 III levels in 2 Italian families with severe thrombophilia.
12 uggest that HAE may be considered a new rare thrombophilia.
13 mal association between perinatal stroke and thrombophilia.
14 rrent pregnancy loss in women with inherited thrombophilia.
15 age, in the presence or absence of inherited thrombophilia.
16 e these complications in pregnant women with thrombophilia.
17 sociated with hemolysis, marrow failure, and thrombophilia.
18 antiphospholipid syndrome (APS) or inherited thrombophilia.
19 y associated with clotting hyperactivity and thrombophilia.
20 ng VTE compared with those without inherited thrombophilia.
21  events than women who screened negative for thrombophilia.
22 e on the cost-effectiveness of screening for thrombophilia.
23 uate the cost-effectiveness of screening for thrombophilia.
24 ies to women with no prior history of VTE or thrombophilia.
25 usly healthy patients, in those with genetic thrombophilia.
26  patients were offered testing for heritable thrombophilia.
27  V Leiden (FVL), is the most common cause of thrombophilia.
28 uding those with and those without inherited thrombophilia.
29 r genetic defects in factor V or concomitant thrombophilia.
30 of BCS comprises several diseases leading to thrombophilia.
31 athophysiology of inherited risk factors for thrombophilia.
32 s thrombosis can be attributed to hereditary thrombophilia.
33  of the association is in the order of other thrombophilias.
34 pecific perinatal stroke diseases with known thrombophilias.
35 es were observed in 12, including all common thrombophilias.
36  carry more prognostic weight than inherited thrombophilias.
37 s did not differ in patients with or without thrombophilia (1.34 [0.73-2.46]; p=0.351).
38 sk of fetal loss was increased in women with thrombophilia (168/571 vs 93/395; odds ratio 1.35 [95% C
39 96]), prior VTE (7.49 [95% CI, 4.29-13.07]), thrombophilia (2.52 [95% CI, 1.04-6.14]), inflammatory b
40                            Of 843 women with thrombophilia 571 had 1524 pregnancies; of 541 control w
41 e, 13%; and (5) psychosocial issues, 7%, and thrombophilia, 7%.
42  identify potentially high-risk patients for thrombophilia and consider testing for inherited risk fa
43 th screening, in order to detect one case of thrombophilia and indeed to prevent a subsequent venous
44 ng pregnancy outcome in women with inherited thrombophilia and placenta-mediated pregnancy complicati
45 in (LMWH) vs no LMWH in women with inherited thrombophilia and prior late (>/=10 weeks) or recurrent
46  C3 and factor D prevented both the systemic thrombophilia and renal TMA phenotypes.
47 ute risk) of gestational VTE associated with thrombophilia and to see whether these risk factors are
48  increased specific activity associated with thrombophilia and used it to improve gene therapy of hem
49 reeclampsia is also associated with maternal thrombophilias and decidual hemorrhage, which form throm
50 inatal stroke include hereditary or acquired thrombophilias and environmental factors.
51 current thrombosis, a history of thrombosis, thrombophilia, and a history of poor pregnancy outcome,
52 of gestational VTE associated with heritable thrombophilia, and current recommendations for antenatal
53 better RBC quality, biomarkers of hemolysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer
54 moking, chronic disease, malignancy, genetic thrombophilia, and procoagulant markers) were adjusted f
55  with recurrent pregnancy loss and inherited thrombophilia, and we advise against screening for inher
56 ore pregnancy losses and confirmed inherited thrombophilia, and who were trying to conceive or were a
57 ologic evaluation for inherited and acquired thrombophilias, and multidisciplinary approaches to trea
58         The most common causes of hereditary thrombophilia are reviewed with an emphasis on resistanc
59                               The hereditary thrombophilias are a group of inherited conditions that
60                                              Thrombophilias are common disorders that increase the ri
61 7 x 10-5), respectively, consistent with the thrombophilia associated with JAK2-mutant MPN.
62 genic or likely pathogenic variants in known thrombophilia-associated genes were identified.
63 t the involvement of thrombotic processes in thrombophilia-associated placental failure.
64 Genetic analysis was performed to detect any thrombophilia-associated variants.
65 egnancy complications in pregnant women with thrombophilia at high risk of these complications and is
66 , we enrolled consenting pregnant women with thrombophilia at increased risk of venous thromboembolis
67 betes mellitus was striking (hazard ratio of thrombophilia-ATE association was 1.41 in nondiabetics v
68                            Future studies on thrombophilia-ATE risk should focus on high-risk populat
69 yndrome (APS) are a major cause for acquired thrombophilia, but specific interventions preventing aut
70 se with prior venous or arterial thrombosis, thrombophilia, cancer (except non-melanoma skin cancer),
71 istory of thrombosis, inherited and acquired thrombophilia, certain medical conditions, and complicat
72 buted to left CRAO, complicating SLE-related thrombophilia, confirmed by fundus fluorescein angiograp
73                      Congenital and acquired thrombophilias contribute to the pathophysiological proc
74 was inducible in 27% of MINOCA patients, and thrombophilia disorders were detected in 14%.
75  first episode of VTE, testing for heritable thrombophilia does not allow prediction of recurrent VTE
76 n (Aalpha R554C-albumin), is associated with thrombophilia ("Dusart Syndrome"), and is characterized
77 rolled in the European Prospective Cohort on Thrombophilia (EPCOT).
78                          Women with familial thrombophilia, especially those with combined defects or
79        Lastly, those with uncommon high-risk thrombophilias, especially those with antithrombin defic
80                                 Standardized thrombophilia evaluations were performed after 12 months
81 is and 2.5% in those without), and inherited thrombophilia (factor V Leiden carriers with a 10-year c
82 erse diseases as hereditary hemochromatosis, thrombophilias, familial cancer predispositions, and pha
83  risk greater than any previously identified thrombophilia genetic risk marker.
84 de evidence that unselected women with these thrombophilias have an increased risk of gestational VTE
85  absence of laboratory evidence of heritable thrombophilia (hazard ratio 1.50 [95% CI 0.82-2.77]; p=0
86 tional components of an extensive laboratory thrombophilia (i.e., hypercoagulability) panel at the ti
87 th markedly elevated FVIII levels and severe thrombophilia in 2 Italian families.
88 gest screening for these forms of hereditary thrombophilia in children with VTE and their relatives.
89                                Understanding thrombophilia in perinatal stroke informs pathogenesis m
90 ng for the causes of hereditary and acquired thrombophilia in selected subsets of patients.
91 nd we advise against screening for inherited thrombophilia in women with recurrent pregnancy loss.
92  While we are now able to diagnose inherited thrombophilias in a substantial number of patients with
93 d nontraditional risk factors (eg, migraine, thrombophilia) in the development of strokes among young
94  their relatives were screened for inherited thrombophilia including proteins C and S and antithrombi
95 sing anti-C5 monoclonal antibodies prevented thrombophilia induced by aPL.
96 important to know whether factors other than thrombophilia influence their risk for thrombosis.
97                           Whether hereditary thrombophilia interacts with traditional cardiovascular
98 tion developed renal TMA as well as systemic thrombophilia involving large blood vessels in multiple
99                                   Hereditary thrombophilia is associated with a slightly increased ri
100                                     Although thrombophilia is associated with a substantial increase
101 the current status of laboratory testing for thrombophilia is discussed.
102                                              Thrombophilia is one of the principal features of paroxy
103 regnancy outcomes in women with constitutive thrombophilia is uncertain.
104    Based on existing evidence, screening for thrombophilia is unlikely to be cost-effective.
105                      Screening for inherited thrombophilia (IT) is controversial; persons at high ris
106 tudy was to estimate the impact of inherited thrombophilia (IT) on the risk of venous thromboembolism
107  VTE but tested negative for known inherited thrombophilias (ITs).
108 mmobility; paresis; previous history of VTE; thrombophilia; malignancy; critical illness; and infecti
109                 The presence of such genetic thrombophilia markers as factor V Leiden, prothrombin 20
110 hrombotic state, we postulated that maternal thrombophilia might be a risk factor for fetal loss.
111 ombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogen
112                  The absence of identifiable thrombophilia mutations suggests that neurologic infecti
113 iopathy, thrombocytopenia, renal injury, and thrombophilia) of COVID-19 that are also observed in oth
114                               No evidence of thrombophilia or causative precipitants was identified.
115  (odds ratio [OR] 21.7, 95% CI 6.8 to 69.1), thrombophilia (OR 25.6, 95% CI 9.2 to 71.2), diabetes me
116 tic anemia, a form of bone marrow failure, a thrombophilia, or any combination of the above.
117 basis of relative prevalences of the various thrombophilias, patients can be classified as "strongly"
118                                 A history of thrombophilia (present in 15% of patients) tended to ass
119  known as the Genetic Analysis of Idiopathic Thrombophilia project (GAIT).
120  recent discoveries of two relatively common thrombophilias, resistance to activated protein C associ
121         Furthermore we have reported genetic thrombophilia results for 271 recipients.
122 e of patient groups, selective history-based thrombophilia screening has been shown to be more cost-e
123 However, the potential cost-effectiveness of thrombophilia screening may be improved if the screening
124  and underscores the importance of pediatric thrombophilia screening programs.
125 ymorphism (n = 279), and women with negative thrombophilia screening results (n = 796).
126  prior fetal death), and women with negative thrombophilia screening results as control women (n = 79
127 these data suggest that women with high-risk thrombophilia should be considered for antenatal thrombo
128 ther than on an algorithmic pathway based on thrombophilia status.
129 nine of 11 participating centres and for all thrombophilia subgroups.
130 atal thromboprophylaxis in women with severe thrombophilia such as homozygous factor V Leiden mutatio
131 n avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transi
132 ical application of the results of inherited thrombophilia testing is nuanced.
133                               The results of thrombophilia testing, not including the FVL mutation, w
134 , as well as the benefits and limitations of thrombophilia testing, will be discussed.
135 ncy terminations had been done in women with thrombophilia than in controls (odds ratio 2.9 [1.8-4.8]
136 ss-linking potential, and contributes to the thrombophilia that characterizes the "Dusart Syndrome."
137 ents), and suggest some guidelines regarding thrombophilia treatment and the management of thrombotic
138 r disease, malignancy, immunodeficiency, and thrombophilia variants were detected in 5.1% (81), 2.1%
139 ctors for post-COVID-19 VTE; factor V Leiden thrombophilia was additionally associated with double th
140                           Further, inherited thrombophilia was associated with an HR of 2.05 (95% CI,
141                                      Genetic thrombophilia was associated with clinical recurrence in
142                                              Thrombophilia was associated with elevated risk of ATE (
143                                              Thrombophilia was not associated with increased risk of
144 c kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA co
145 c kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA co
146       Genetic or acquired conditions causing thrombophilia were rare.
147                 Moreover, the association of thrombophilia with ATE tended to be stronger in females
148                  Overall, the association of thrombophilia with ATE tended to be stronger in the pres
149 actors, especially the synergistic effect of thrombophilia with diabetes mellitus was striking (hazar
150 erial thrombosis and discuss our approach to thrombophilia workup in patients after an unexplained ar
151 s before 15 weeks' gestation) and a negative thrombophilia workup.

 
Page Top